Cristina Oliveras-Ferraros
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Cristina Oliveras-Ferraros has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Alejandro Vazquez-Martin
Translational Research Laboratory; Catalan Institute of Oncology; Girona, Catalonia, Spain; Girona Biomedical Research Institute; Girona, Catalonia, Spain
2 shared publications - Javier A. Menendez
Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology, Girona, Spain
2 shared publications - Anna Rull
Hospital Universitari de Tarragona Joan XXIII (HJ23), Tarragona, Spain
1 shared publication - Begoña Martin-Castillo
Unit of Clinical Research, Catalan Institute of Oncology (ICO)–Girona, 17007 Girona, Spain
1 shared publication - Carlos Alonso-Villaverde
Institut Català de Ciències Cardiovasculars, Centre superior d'Investigacions Científiques, Barcelona, Spain
1 shared publication - Fernando Rodríguez-Sanabria
Centre de Recerca Biomèdica, Hospital Universitari de Sant Joan, Institut d'Investigació Sanitària Pere Virgili (IISPV), Universitat Rovira i Virgili, Reus, Spain
1 shared publication
Latest Publications
- Open Access
- 24 January 2011
- Published by Springer Nature in Breast Cancer Research
- Vol. 13 (1) , 401
Circulating fatty acid synthase: an exploratory biomarker to predict efficacy of the dual HER1/HER2 tyrosine kinase inhibitor lapatinib
- 24 January 2011
- Published by Springer Nature in Breast Cancer Research
- Vol. 13 (1) , 401
Open AccessCirculating fatty acid synthase: an exploratory biomarker to predict efficacy of the dual HER1/HER2 tyrosine kinase inhibitor lapatinib
- Open Access
- 13 August 2010
- Published by Springer Nature in BMC Gastroenterology
- Vol. 10 (1) , 92
Infection with HIV and HCV enhances the release of fatty acid synthase into circulation: evidence for a novel indicator of viral infection
Background: Fatty acid synthase (FASN) is an enzyme synthesized by the liver and plays an important role in lipogenesis. The present study aimed to investigate whether serum FASN concentration may provide a direct link between HIV and/or HCV viral infections and lipid metabolic disorders commonly observed in HIV/HCV-infected patients.Methods: We evaluated serum FASN concentration in 191 consecutive HIV-infected patients in the absence or presence of HCV co-infection. For comparison, 102 uninfected controls were included. Metabolic and inflammatory phenotype was also compared with respect to the presence of HCV co-infection.Results: Serum FASN concentration was significantly higher in HIV-infected patients than in healthy participants and HCV co-infected patients showed higher levels than those without co-infection. Levels were also affected by treatment regimen, but marginally influenced by virological variables. Insulin concentration was the sole variable among metabolic parameters that demonstrated a significant correlation with serum FASN concentrations. Serum alanine aminotransferase (ALT) values correlated significantly with serum FASN concentration and provided the best discrimination with respect to the presence or absence of HCV co-infection. In multivariate analysis, only ALT, monocyte chemoattractant protein-1 (MCP-1) and the presence of antiretroviral treatment regimen significantly contributed to explain serum FASN concentration in HIV/HCV co-infected patients.Conclusion: Serum FASN concentration is significantly increased in HIV-infected individuals. The release of FASN into the circulation is further enhanced in patients who are co-infected with HCV. Subsequent studies should explore the usefulness of this indicator to monitor the effect of viral infections on disease progression and survival.
- 13 August 2010
- Published by Springer Nature in BMC Gastroenterology
- Vol. 10 (1) , 92
Open AccessInfection with HIV and HCV enhances the release of fatty acid synthase into circulation: evidence for a novel indicator of viral infection
Background: Fatty acid synthase (FASN) is an enzyme synthesized by the liver and plays an important role in lipogenesis. The present study aimed to investigate whether serum FASN concentration may provide a direct link between HIV and/or HCV viral infections and lipid metabolic disorders commonly observed in HIV/HCV-infected patients.Methods: We evaluated serum FASN concentration in 191 consecutive HIV-infected patients in the absence or presence of HCV co-infection. For comparison, 102 uninfected controls were included. Metabolic and inflammatory phenotype was also compared with respect to the presence of HCV co-infection.Results: Serum FASN concentration was significantly higher in HIV-infected patients than in healthy participants and HCV co-infected patients showed higher levels than those without co-infection. Levels were also affected by treatment regimen, but marginally influenced by virological variables. Insulin concentration was the sole variable among metabolic parameters that demonstrated a significant correlation with serum FASN concentrations. Serum alanine aminotransferase (ALT) values correlated significantly with serum FASN concentration and provided the best discrimination with respect to the presence or absence of HCV co-infection. In multivariate analysis, only ALT, monocyte chemoattractant protein-1 (MCP-1) and the presence of antiretroviral treatment regimen significantly contributed to explain serum FASN concentration in HIV/HCV co-infected patients.Conclusion: Serum FASN concentration is significantly increased in HIV-infected individuals. The release of FASN into the circulation is further enhanced in patients who are co-infected with HCV. Subsequent studies should explore the usefulness of this indicator to monitor the effect of viral infections on disease progression and survival.